PCOS.

Summary

GLP-1 receptor agonists have emerging evidence from clinical studies supporting their repurposing in PCOS. They have been shown to be effective in regulating menstrual cycles in adolescents with PCOS, in addition to improving metabolic parameters including weight reduction, insulin sensitivity, and glucose homeostasis. Multiple reviews and systematic searches of ClinicalTrials.gov identify GLP-1 RAs as promising repurposed medications for PCOS with supporting clinical data.

Summary

Multiple RCTs demonstrate that myo-inositol (MI) improves ovarian function, menstrual regularity, fertility, hyperandrogenism (acne and hirsutism), insulin resistance, and hormonal parameters in women with PCOS. A review identified 47 clinical trials (35 RCTs) supporting these effects. In lean PCOS teenagers (ages 13-19), myo-inositol alone or combined with oral contraceptives significantly decreased weight and BMI, improved metabolic profiles (insulin sensitivity), and ameliorated hormonal parameters including LH/FSH ratio and testosterone levels. The combination of MI and D-chiro-inositol in a 40:1 physiological ratio shows benefits for metabolic, hormonal, and reproductive aspects of PCOS.

Summary

HMG-CoA reductase inhibitors (statins) have supporting data for repurposing in PCOS, as noted in reviews of ClinicalTrials.gov and published literature. Statins may improve lipid profiles, reduce androgen levels, and have anti-inflammatory effects in women with PCOS. They are listed among repurposed medications with clinical evidence, though the number of completed clinical trials remains limited.

Summary

Metformin is the most widely studied and used off-label drug for PCOS. It is recognized by the ADA and international guidelines for PCOS management. In adolescents with PCOS, metformin at dosages of 1500-2550 mg/day is effective in regulating menstrual cycles, improving insulin sensitivity, and aiding weight management, particularly in overweight patients. It is considered the most effective and cost-efficient non-hormonal treatment when oral contraceptives are contraindicated. Metformin improves metabolic disturbances (glucose tolerance, insulin resistance), hormonal parameters, and ovarian function in women with PCOS across multiple clinical studies.

Summary

Multiple reviews synthesizing RCT evidence report that vitamin D supplementation may be beneficial in PCOS, with women with PCOS frequently found to be vitamin D deficient. Supplementation has been associated with improvements in insulin resistance, metabolic parameters, and hormonal profiles. Vitamin D is listed among nutrients with evidence from RCTs, systematic reviews, and meta-analyses supporting its use as an adjunct therapy in PCOS management.

Summary

Out of 28,321 condition-relevant adverse event reports for spironolactone in the FDA AEMS database (from 73,834 total female-patient reports), the data reveals a pattern of androgenetic alopecia (n=1), acne (n=2), alopecia (n=5), weight increased (n=8), glucose tolerance impaired (n=2), hyperglycaemia (n=2), and menstrual disturbances including amenorrhoea (n=1) and menorrhagia (n=1). Spironolactone is a well-established anti-androgen used off-label in PCOS, and these adverse events—particularly metabolic disruption and menstrual irregularity—reflect its direct engagement with the androgen receptor and mineralocorticoid pathways central to PCOS pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are identified as novel insulin sensitizers with supporting clinical trial data for repurposing in PCOS. They are listed among emerging therapies in multiple reviews summarizing ClinicalTrials.gov registered studies and clinical evidence. Their potential benefits in PCOS include improvement of insulin resistance, weight reduction, and metabolic parameters, though completed clinical trials remain few with small populations.

Summary

In a study of lean PCOS teenagers, drospirenone/ethinylestradiol oral contraceptive pills were used as a comparator to myo-inositol. The OCP was effective in managing PCOS symptoms in the 17-19 year age group, and when combined with myo-inositol, prevented increases in weight and BMI while strongly ameliorating hormonal parameters. In the 13-16 age group, myo-inositol alone was preferred, but the combination approach in older teens showed complementary benefits for both metabolic and hormonal profiles.

Summary

In NCT01483118, cinnamon extract studied for menstrual cycle regulation in PCOS produced menstrual cramps (n=9), headache (n=19), migraine (n=3), anxiety (n=1), and insomnia (n=1). The appearance of menstrual cramps (dysmenorrhea) in a population being treated for cycle irregularity may indicate that cinnamon extract's insulin-sensitizing effects are restoring ovulatory menstrual cycles, with the associated dysmenorrhea reflecting return of normal cyclicity.

Summary

Out of 12,085 condition-relevant adverse event reports for liraglutide in the FDA AEMS database (from 29,717 total female-patient reports), metabolic signals strongly relevant to PCOS were observed including blood glucose increased (n=25), weight decreased (n=9), blood glucose decreased (n=9), weight increased (n=8), hyperglycaemia (n=2), blood glucose abnormal (n=2), hypoglycaemia (n=2), alopecia (n=1), blood thyroid stimulating hormone increased (n=1), and impaired insulin secretion (n=1). Liraglutide has published clinical evidence for improving PCOS outcomes, and the AEMS metabolic signal profile confirms its deep engagement with insulin-glucose homeostasis — the central driver of PCOS pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

In NCT00611923, flutamide was studied in PMDD/PMS and its androgen receptor antagonism is directly relevant to PCOS pathophysiology. While the trial was not conducted in PCOS patients, flutamide's mechanism of blocking androgen receptor signaling addresses the hyperandrogenism that is a hallmark of PCOS. AEs of headache (n=6) and fatigue (n=1) are non-specific, but the anti-androgenic mechanism has established relevance to PCOS symptom management including hirsutism, acne, and metabolic dysregulation.

Summary

In NCT03749109, a trial of quinagolide vaginal ring for lesion reduction in women with endometriosis/adenomyosis, ovarian cyst was reported in 3 subjects. This AE pattern may reflect the drug's dopamine agonist activity modulating prolactin and downstream gonadotropin signaling, which could alter ovarian follicular dynamics relevant to PCOS pathophysiology.

Summary

Rosiglitazone is a PPARγ agonist approved for type 2 diabetes, currently in Phase 2 for endometriosis. PPARγ activation directly antagonizes estrogen receptor 1 (ESR1) transcriptional activity via competition for shared coactivators and suppresses NF-κB-driven inflammatory cytokine production including IL-1α (literature score 0.84). ESR1 is the top-scoring target for endometriosis (overall 0.670, clinical 0.90), and IL-1α has a genetic association score of 0.73.

Summary

Ergocalciferol (vitamin D2) activates the vitamin D receptor (VDR), a nuclear receptor that regulates over 200 genes including those involved in insulin signaling, steroidogenesis, and inflammation. VDR is expressed in ovarian granulosa cells and regulates anti-Müllerian hormone (AMH) expression, which is pathologically elevated in PCOS. PCOS patients show high prevalence of vitamin D deficiency correlating with insulin resistance severity. CYP19A1 (aromatase, Open Targets literature=0.96) is a VDR transcriptional target.

Summary

Semaglutide (GLP-1R agonist) is in Phase 3 for PCOS. GLP-1 receptor signaling improves pancreatic beta cell function, reduces appetite, and enhances insulin sensitivity. PCOS is genetically linked to metabolic targets — FTO (score=0.424, literature=0.85) is one of the strongest obesity-associated loci, and THADA (score=0.430, genetic=0.68) is linked to beta cell dysfunction. The convergence of weight loss, insulin sensitization, and potential direct ovarian effects makes this a multi-target intervention.

Summary

Melatonin acts via MT1R (MTNR1A) and MT2R (MTNR1B) receptors. MTNR1B genetic variants are among the strongest GWAS hits for type 2 diabetes risk through impaired beta-cell insulin secretion, and insulin resistance is a core PCOS driver. PCOS patients frequently show disrupted circadian rhythms and altered melatonin profiles. The genetic association between MTNR1B and glucose homeostasis provides a plausible mechanistic link.

Summary

Mirabegron is a beta-3 adrenergic receptor (ADRB3) agonist approved for overactive bladder, now in Phase 1 for PCOS. Beta-3 adrenergic receptor activation stimulates lipolysis and thermogenesis in brown/beige adipose tissue and improves insulin sensitivity. PCOS is fundamentally linked to insulin resistance and metabolic dysfunction, with metformin (mitochondrial complex I inhibitor) already in Phase 3 trials. The NADH:ubiquinone oxidoreductase subunits show clinical evidence scores of 0.68 for PCOS, confirming mitochondrial metabolic pathway involvement.

Summary

Dapagliflozin (SGLT2 inhibitor) is in Phase 3 for PCOS. SGLT2 inhibition produces glycosuria, reducing circulating glucose and insulin levels independent of insulin signaling. Compensatory hyperinsulinemia is a core driver of PCOS pathophysiology — insulin synergizes with LH to stimulate theca cell androgen production via CYP17A1 upregulation. CYP19A1 (aromatase) has an Open Targets literature score of 0.96, and ESR1 has an overall score of 0.573, confirming the centrality of steroid hormone dysregulation.

Summary

Pioglitazone is a PPARγ agonist approved for type 2 diabetes, now in Phase 2 for PCOS. PPARγ is a master regulator of adipogenesis, insulin sensitization, and anti-inflammatory signaling. PCOS has strong genetic and clinical links to insulin resistance pathways — FTO (Open Targets score 0.424, literature=0.85) is a known obesity/metabolic risk locus, and THADA (score=0.430, genetic=0.68) is implicated in pancreatic beta cell function and insulin secretion.

Summary

Raloxifene is a selective estrogen receptor modulator (SERM) acting on ESR1 and ESR2. ESR1 (estrogen receptor 1) has the highest overall Open Targets association score for PCOS at 0.573 (clinical=0.89, literature=0.80, animal_model=0.57). Unlike clomiphene which is already used in PCOS for ovulation induction, raloxifene's tissue-selective ER modulation — antagonist in breast/uterus, agonist in bone — has not been systematically explored for PCOS endometrial protection or metabolic effects.

Summary

Pavinetant is a neurokinin 3 receptor (NK3R/TACR3) antagonist developed for menopausal hot flashes. NK3R signaling through kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the hypothalamic arcuate nucleus directly regulates GnRH pulse frequency. PCOS is characterized by increased GnRH pulse frequency leading to elevated LH:FSH ratio. The GnRH receptor has an Open Targets overall score of 0.475 for PCOS (literature=0.81, clinical=0.73).

Summary

Simvastatin (HMG-CoA reductase inhibitor) is in Phase 3 for PCOS. HMG-CoA reductase sits upstream of the cholesterol biosynthesis pathway that feeds steroidogenesis — the mevalonate pathway provides the substrate for all steroid hormones including androgens. PCOS's hallmark hyperandrogenism depends on ovarian and adrenal steroidogenesis from cholesterol precursors. CYP19A1 (aromatase) has an Open Targets literature score of 0.96 for PCOS, confirming the centrality of steroid biosynthesis.

Summary

Out of 48,546 condition-relevant adverse event reports for atorvastatin in the FDA AEMS database (from 123,129 total female-patient reports), a substantial metabolic signal cluster includes glucose tolerance impaired (n=9), weight increased (n=7), blood glucose increased (n=4), hyperglycaemia (n=2), and type 2 diabetes mellitus (n=38) with hirsutism (n=1). The general sample overwhelmingly confirms type 2 diabetes mellitus (n=75) as the dominant adverse event, indicating strong diabetogenic potential with direct relevance to PCOS insulin resistance and metabolic pathology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 46,392 condition-relevant adverse event reports for rosuvastatin in the FDA AEMS database (from 107,207 total female-patient reports), metabolic and hormonal disruption signals include blood glucose increased (n=4), weight increased (n=5), weight decreased (n=9), acne (n=2), blood glucose decreased (n=2), alopecia (n=2), and glucose tolerance impaired (n=1), with the general sample confirming type 2 diabetes mellitus (n=27) as the dominant co-reported condition. This metabolic disruption profile is directly relevant to PCOS insulin resistance pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 25,166 condition-relevant adverse event reports for tirzepatide in the FDA AEMS database (from 74,456 total female-patient reports), robust metabolic and hormonal signals directly relevant to PCOS were observed, including weight decreased (n=19), weight increased (n=8), weight fluctuation (n=8), blood glucose increased (n=6), glucose tolerance impaired (n=4), alopecia (n=4), insulin resistance (n=1), and a direct report of polycystic ovarian syndrome (n=1). The explicit PCOS mention alongside the insulin resistance and glucose tolerance signals strongly corroborates tirzepatide's engagement with core PCOS pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 20,277 condition-relevant adverse event reports for dulaglutide in the FDA AEMS database (from 44,406 total female-patient reports), metabolic signals highly relevant to PCOS included blood glucose increased (n=20), weight increased (n=6), weight decreased (n=6), blood glucose decreased (n=3), blood glucose abnormal (n=3), hypoglycaemia (n=2), and alopecia (n=1). The general sample confirmed weight decrease as a prominent effect (n=4). The metabolic signal profile confirms dulaglutide's engagement with insulin-glucose homeostasis pathways central to PCOS pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 19,508 condition-relevant adverse event reports for exenatide in the FDA AEMS database (from 32,744 total female-patient reports), metabolic signals relevant to PCOS were the most prominent of any drug in this class, with blood glucose increased (n=31), weight decreased (n=13), blood glucose decreased (n=12), weight increased (n=7), blood glucose fluctuation (n=6), blood glucose abnormal (n=4), hyperglycaemia (n=3), hypoglycaemia (n=2), and overweight (n=1). The general sample confirmed weight decrease (n=8) as a leading effect. Exenatide's strong insulin-sensitizing metabolic signature directly addresses the hyperinsulinemic driver of PCOS. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 1,648 condition-relevant adverse event reports for rotigotine in the FDA AEMS database (from 6,009 total female-patient reports), pain signals (abdominal pain n=9, headache n=8, pain n=7, pain in extremity n=7) and inflammatory markers (peripheral swelling n=4, oedema peripheral n=3, inflammation n=2, generalised oedema n=2) alongside polycystic ovaries (n=2) and hirsutism (n=1) represent a combined pain-inflammatory-hormonal signal. The notable finding of polycystic ovaries (n=2) in a Parkinson's/RLS drug population, combined with metabolic signals (weight increased n=2, blood glucose increased n=1, hirsutism n=1), suggests dopaminergic modulation of the HPG axis relevant to PCOS. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,176 condition-relevant adverse event reports for pramipexole in the FDA AEMS database (from 10,301 total female-patient reports), metabolic signals included weight increased (n=7), weight decreased (n=3), blood glucose abnormal (n=1), glucose urine (n=1), blood glucose fluctuation (n=1), overweight (n=1), and acne (n=1). The general sample corroborated metabolic effects with hypoglycaemia (n=2) and weight decreased (n=3). Combined with pramipexole's known D3-mediated effects on hypothalamic metabolic circuits and its pharmacological similarity to bromocriptine (FDA-approved for T2DM), this signal is relevant to PCOS insulin resistance and metabolic dysfunction. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 131 condition-relevant adverse event reports for bromocriptine in the FDA AEMS database (from 316 total female-patient reports), robust metabolic signals emerged with blood glucose decreased (n=7), blood glucose increased (n=5), weight decreased (n=7), weight increased (n=5), hyperglycaemia (n=2), and hormonal disruptions including FSH abnormalities and thyroid perturbations. Bromocriptine is already FDA-approved for type 2 diabetes (Cycloset), validating the metabolic pathway engagement seen in AEMS, and this dopaminergic metabolic modulation is directly relevant to PCOS insulin resistance and hyperandrogenism. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 999 condition-relevant adverse event reports for cabergoline in the FDA AEMS database (from 2,447 total female-patient reports), prominent metabolic signals included weight increased (n=13), weight decreased (n=15), blood glucose increased (n=5), hyperglycaemia (n=3), glucose tolerance impaired (n=2), and hirsutism (n=1), alongside hormonal perturbations including hormone level abnormal (n=6) and alopecia (n=6). These metabolic-hormonal disruption patterns are directly relevant to PCOS pathophysiology, where dopamine agonists are known to modulate insulin sensitivity and androgen levels through hypothalamic-pituitary modulation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,313 condition-relevant adverse event reports for ropinirole in the FDA AEMS database (from 10,302 total female-patient reports), metabolic/hormonal signals included weight increased (n=6), weight decreased (n=6), blood glucose increased (n=2), hyperglycaemia (n=1), alopecia (n=2), and thyroid perturbations (TSH decreased n=1, TSH increased n=1), with the general sample showing obesity-related co-morbidities. As a D2/D3 agonist in the same pharmacological class as bromocriptine (FDA-approved for T2DM), ropinirole's metabolic modulation is relevant to PCOS insulin resistance, particularly through hypothalamic dopaminergic regulation of circadian metabolic rhythms. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 35,251 condition-relevant adverse event reports for fluoxetine in the FDA AEMS database (from 83,971 total female-patient reports), metabolic and menstrual signals relevant to PCOS were identified including weight increased (n=8), blood glucose increased (n=2), amenorrhoea (n=3), menstruation irregular (n=2), menstrual disorder (n=2), ovarian failure (n=1), alopecia (n=3), and blood thyroid stimulating hormone decreased (n=1). Fluoxetine-induced metabolic changes may interact with insulin resistance pathways central to PCOS, while menstrual disruption signals suggest hypothalamic-pituitary-gonadal axis modulation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 34,200 condition-relevant adverse event reports for citalopram in the FDA AEMS database (from 83,257 total female-patient reports), metabolic signals relevant to PCOS were identified including weight increased (n=5), weight decreased (n=5), alopecia (n=4), hyperglycaemia (n=1), blood glucose increased (n=1), blood glucose abnormal (n=1), alongside mood signals (depression n=18, anxiety n=5). These metabolic perturbations are relevant to the insulin resistance and weight management challenges central to PCOS, and SSRI-induced weight gain may worsen androgenic symptoms. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 54,612 condition-relevant adverse event reports for sertraline in the FDA AEMS database (from 130,278 total female-patient reports), metabolic signals relevant to PCOS were identified including weight increased (n=9), weight decreased (n=3), alopecia (n=6), and weight abnormal (n=1), alongside menstrual disruption signals (amenorrhoea n=1, menorrhagia n=1, metrorrhagia n=1). SSRI-induced weight gain and metabolic perturbation may exacerbate insulin resistance and androgen excess in women with PCOS. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,976 condition-relevant adverse event reports for escitalopram in the FDA AEMS database (from 85,593 total female-patient reports), metabolic signals relevant to PCOS were identified including weight increased (n=6), weight decreased (n=6), alopecia (n=6), abnormal loss of weight (n=2), glucose tolerance impaired (n=1), blood glucose increased (n=1), overweight (n=1), alongside menstrual disruption (menstruation irregular n=1, menorrhagia n=1). The bidirectional weight signals and glucose impairment in the context of SSRI use are relevant to the metabolic-hormonal dysregulation in PCOS. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 17,165 condition-relevant adverse event reports for meloxicam in the FDA AEMS database (from 37,086 total female-patient reports), metabolic/hormonal signals include alopecia (n=6), weight decreased (n=4), weight increased (n=4), dermatitis acneiform (n=1), acne (n=1), blood glucose abnormal (n=1), hormone level abnormal (n=1), blood glucose increased (n=1), and ovarian cyst (n=1). This metabolic-androgenic pattern, combined with significant weight fluctuation and the ovarian cyst report, is directly relevant to PCOS metabolic and ovarian pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,972 condition-relevant adverse event reports for celecoxib in the FDA AEMS database (from 83,065 total female-patient reports), metabolic signals including weight increased (n=4), glucose tolerance impaired (n=1), blood glucose increased (n=1), and overweight (n=1) alongside alopecia (n=1) form a metabolic cluster. These signals, combined with celecoxib's known effects on prostaglandin-mediated insulin signaling, are relevant to PCOS metabolic dysfunction. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 68,147 condition-relevant adverse event reports for ibuprofen in the FDA AEMS database (from 159,407 total female-patient reports), metabolic and hormonal signals include weight increase (n=3), acne (n=1), alopecia (n=1), glucose tolerance impaired (n=1), and infertility (n=1), alongside menstrual irregularity (n=2). While individually small, these converge on metabolic-hormonal disruption relevant to PCOS pathophysiology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 38,880 condition-relevant adverse event reports for naproxen in the FDA AEMS database (from 85,294 total female-patient reports), metabolic signals including weight increased (n=10), alopecia (n=4), acne (n=1), blood glucose increased (n=1), and menstrual irregularity (n=1) form a pattern relevant to PCOS metabolic-hormonal dysregulation. The weight gain signal is notable at 10% of the sampled reports and is corroborated by fluid retention (peripheral swelling n=10). Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 37,836 condition-relevant adverse event reports for diclofenac in the FDA AEMS database (from 86,286 total female-patient reports), metabolic/hormonal signals include weight increased (n=8), weight decreased (n=5), alopecia (n=3), blood glucose abnormal (n=3), blood glucose decreased (n=2), and Cushing's syndrome (n=1). The weight gain and glucose abnormality cluster, alongside fluid retention (peripheral swelling n=3, oedema peripheral n=3, oedema n=2), suggests metabolic perturbation relevant to PCOS insulin resistance pathways. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 15,012 condition-relevant adverse event reports for anastrozole in the FDA AEMS database (from 31,213 total female-patient reports), metabolic and hormonal signals including weight increased (n=3), weight decreased (n=5), alopecia (n=7), acne (n=1), blood glucose decreased (n=1), and ovarian failure (n=1) alongside amenorrhoea (n=1) reflect the androgenic shift from aromatase blockade relevant to PCOS. Anastrozole is being studied for PCOS ovulation induction similarly to letrozole, and the relative hyperandrogenism from blocked estrogen conversion mirrors core PCOS endocrinology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 24,875 condition-relevant adverse event reports for letrozole in the FDA AEMS database (from 54,797 total female-patient reports), metabolic signals including weight increased (n=4), hyperglycaemia (n=2), blood glucose increased (n=1), glucose tolerance impaired (n=1), acne (n=1), blood FSH increased (n=1), and blood LH increased (n=1) are consistent with the relative hyperandrogenic state created by aromatase inhibition, directly relevant to PCOS pathophysiology. Letrozole is already FDA-recognized as an ovulation induction agent for PCOS, and these metabolic adverse events mirror the metabolic syndrome features of PCOS itself. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,735 condition-relevant adverse event reports for exemestane in the FDA AEMS database (from 18,954 total female-patient reports), metabolic-hormonal signals including weight increased (n=5), hyperglycaemia (n=3), acne (n=4), alopecia (n=2), weight decreased (n=6), glucose tolerance impaired (n=1), blood FSH increased (n=1), and blood LH increased (n=1) are consistent with a hyperandrogenic metabolic profile relevant to PCOS. Exemestane's steroidal structure means it can also interact with androgen receptors as a weak androgen, adding a unique pharmacological dimension to its PCOS-relevant endocrine effects beyond simple aromatase blockade. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,493 condition-relevant adverse event reports for naltrexone in the FDA AEMS database (from 18,974 total female-patient reports), metabolic and hormonal signals included blood glucose decreased (n=3), blood glucose increased (n=1), weight decreased (n=2), acne cystic (n=1), and alopecia (n=1), alongside mood disturbance. Naltrexone's opioid receptor antagonism modulates hypothalamic GnRH pulsatility and insulin signaling pathways implicated in PCOS pathophysiology, and naltrexone has been studied as an adjunct in PCOS for reducing LH hypersecretion. Full-scale analysis of all reports may reveal additional patterns.

Summary

Multiple users report that after starting inositol supplementation, they experienced reduced sugar/carb cravings, improved mood and sleep, decreased bloating/water retention, weight loss, more regular menstrual cycles, reduced anxiety, and improvements in skin appearance. Several users report these changes occurring within days to weeks of starting the supplement.

Summary

Multiple users report drinking spearmint tea daily to reduce facial hair growth and lower androgens. Users describe it as a natural anti-androgen approach, often combined with other supplements, and report reduced or thinner facial/body hair growth after consistent use over weeks to months.

Summary

Multiple users report taking saw palmetto as a natural anti-androgen alternative to spironolactone, describing reduced testosterone levels, thinner body/facial hair, and improved PCOS symptoms after several months of consistent use. Users describe it as a 'natural version of spiro' for blocking testosterone.

Summary

Multiple users report that after starting GLP-1 receptor agonist medications (originally developed for type 2 diabetes), they experienced significant weight loss, quieting of 'food noise' and constant hunger, improved insulin resistance, and emotional relief from finally having a treatment that addresses their PCOS-related metabolic dysfunction. Users describe these medications as transformative for PCOS weight management when diet and exercise alone failed.

Summary

Multiple users report that after discovering severe vitamin D deficiency and starting high-dose supplementation (often prescribed 50,000 IU/week), they experienced significant hair regrowth, improved energy, and amelioration of PCOS symptoms that had not responded to other treatments. Users emphasize that vitamin D deficiency is very common in PCOS and often overlooked by doctors.